Back

Gazing into the future opportunities of glucagon-like peptide-1 receptor agonists in cardiovascular disease

1 September 2019 (13:20 - 13:40)
Organised by:
Congress Presentation Part of: Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease Diabetes and the Heart ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

4 More presentations in this session

Presentation thumbnail
Chair’s Welcome
Professor L. Ryden (Stockholm, SE)
Video
Presentation thumbnail
Examining the link: type 2 diabetes and cardiovascular disease
Professor L. Ryden (Stockholm, SE)
Slides Video
Presentation thumbnail
“Belling the Cat” - Practical guide for cardiologists on Incorporating GLP-1RAs into comprehensive cardiovascular risk reduction
Doctor M. Kosiborod (Kansas City, US)
Video
Presentation thumbnail
Connecting with the speakers - Questions and answers
Professor L. Ryden (Stockholm, SE) Professor S. Verma (Toronto, CA) Doctor M. Kosiborod (Kansas City, US)
Video

Access the full session

Session thumbnail
Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease

The Event

Event poster

ESC Congress 2019

1 September 2019 13:20 CET
You may be interested in
thumbnail
Congress Presentation
Effects of the glucagon like peptide-1 receptor analogue, sodium-glucose co-transporter 2 and their combination on myocardial work index and vascular function in diabetes after 3-month treatment
3 September 2019
thumbnail
Webinar
GLP-1 RAs and HFpEF : what do we know from large RCTs about GLP-1 RAs and their effects on HFpEF?
24 November 2025
thumbnail
Congress Session
GLP-1 RAs: more than just glucose-lowering agents
28 August 2022
thumbnail
Congress Presentation
GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources